期刊文献+

无功能垂体腺瘤药物治疗的研究进展 被引量:1

Advances in Medical Treatment of Clinically Nonfunctioning Pituitary Adenomas
下载PDF
导出
摘要 无功能垂体腺瘤是垂体腺瘤中最常见的类型,由于缺乏临床症状和激素高分泌状态,一般发现较晚。虽然无功能垂体腺瘤是良性肿瘤,但由于诊断时肿瘤往往已侵犯周围组织,手术很难全部切除,且术后易复发。近年来,药物治疗垂体腺瘤的研究取得了飞速进展,药物能使部分无功能垂体腺瘤患者肿瘤体积缩小,临床症状改善。 Clinically nonfunctioning pituitary adenomas are the most common types among pituitary adenomas. These tumors are usually diagnosed in their later stages due to the absence of clinical symptoms and detectable hormonal hypersecretion. Although these tumors are benign, they are hard to be completely removed during neurosurgery due to the massive invasion into the surrounding tissues at diagnosis. Furthermore, relapse is common. In recent years, medical treatment of pituitary adenomas has witnessed a rapid development. New medications have shown certain effectiveness in reducing the tumor size and improving the clinical symptoms.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2012年第3期298-302,共5页 Acta Academiae Medicinae Sinicae
关键词 无功能垂体腺瘤 药物治疗 nonfunctioning pituitary adenomas medical treatment
  • 相关文献

参考文献32

  • 1Ezzat S,Asa SL,Couldwell WT. The prevalence of pituitary adenomas:a systematic review[J].Cancer,2004,(03):613-619.doi:10.1002/cncr.20412.
  • 2Jaffe CA. Clinically non-functioning pituitary adenoma[J].Pituitary,2006,(04):317-321.doi:10.1007/s11102-006-0412-9.
  • 3Alameda HC,Lahera VM,Varela DCC. Treatment of clinically nonfunctioning pituitary adenomas[J].Endocrinologia Y Nutricion,2010,(02):71-81.doi:10.2165/11532240-000000000-00000.
  • 4Pawlikowski M,Pisarek H,Kunert-Radek J. Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas[J].Endocrine Pathology,2003,(03):231-238.
  • 5Taboada GF,Luque RM,Bastos W. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas[J].European Journal of Endocrinology,2007,(01):65-74.doi:10.1530/eje.1.02313.
  • 6Broson-Chazot F,Houzard C,Ajzenberg C. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas:correlation with hormonal and visual responses to octreotide[J].Clinical Endocrinology(Oxford),1997,(05):589-598.
  • 7Colao A,Di Somma C,Pivonello R. Medical therapy for clinically non-functioning pituitary adenomas[J].Endocrine-Related Cancer,2008,(04):905-915.doi:10.1677/ERC-08-0181.
  • 8Florio T,Thellung S,Arena S. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cellsin vitro[J].European Journal of Endocrinology,1999,(04):396-408.doi:10.1530/eje.0.1410396.
  • 9Ono K,Suzuki T,Miki Y. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727[J].Anticancer Research,2007,(4B):2231-2239.
  • 10Zatelli M C,Piccin D,Vignali C. Pasireotide,a multiple somatostatin receptor subtypes ligand,reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion[J].Endocr RelatCancer,2007,(01):91-102.

同被引文献17

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部